The antibiotic paradox: why companies can’t afford to create life-saving drugs

The antibiotic paradox: why companies can’t afford to create life-saving drugs

The market is killing new antibiotics Antibiotics are one of the world’s most desperately needed classes of drug. Yet many of the companies developing them are struggling to survive. In the last 2 years, the companies that made 5 of the 15 antibiotics approved by the US Food and Drug Administration since 2010 have declared bankruptcy or put themselves up for sale. Nature investigates the bitter paradox that is hobbling efforts to solve one of humanity’s greatest challenges. Nature | 13 min read